All Articles

In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers. Read More ›

Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer. Read More ›

In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting. Read More ›

This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer. Read More ›

To improve survival in patients with biliary tract cancer, researchers are studying combinations of immunotherapy and poly-ADP ribose polymerase inhibitors; the BilT-02 study is summarized. Read More ›

Researchers present preliminary findings from the HERIZON-BTC-01 study, which investigated zanidatamab’s efficacy in patients with HER2-positive biliary tract cancer. Read More ›

In a subanalysis of the STAMP trial, circulating tumor DNA was assessed for its clinical effectiveness in detecting molecular residual disease in patients with cholangiocarcinoma. Read More ›

In patients with biliary tract cancer, EGFR amplifications and FGFR3 fusions may serve as important predictive biomarkers and as potential targets for anticancer therapy in the future. Read More ›

An analysis of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies was presented by Pashtoon Kasi, MD, MS. Read More ›

Two phase 1a/1b dose-escalation/expansion trials investigated the efficacy and safety of MDM2-p53 antagonist BI 907828 in patients with advanced biliary tract cancer. Read More ›